NCT06183918 (Tranexamicacid) is a Phase 4 clinical trial of Tranexamic acid in Anterior Epistaxis, sponsored by Izmir Ataturk Training and Research Hospital.

Who is sponsoring NCT06183918?

NCT06183918 is sponsored by Izmir Ataturk Training and Research Hospital.

What drugs are being tested in NCT06183918?

Interventions in NCT06183918: Tranexamic acid, Saline.

What condition does NCT06183918 study?

NCT06183918 studies Anterior Epistaxis, Tranexamic Acid.

Is NCT06183918 still recruiting?

NCT06183918 is currently completed. Last updated 28 December 2023.

Last reviewed 2023-12-28 · How we verify

NCT06183918: Tranexamicacid

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tranexamic Acid Dosage for Topical Treatment of Anterior Epistaxis

Completed Phase 4 Last updated 28 December 2023

What this trial tests

Phase 4 trial testing Tranexamic acid in Anterior Epistaxis in 152 participants. Completed in 15 March 2023.

Timeline

16 December 2021

Primary endpoint
31 December 2022

15 March 2023

Quick facts

Lead sponsor	Izmir Ataturk Training and Research Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	152
Start date	16 December 2021
Primary completion	31 December 2022
Estimated completion	15 March 2023
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Tranexamic acid (Tranexamic Acid) — full drug profile →
Saline

Conditions studied

Anterior Epistaxis — all drugs for Anterior Epistaxis →
Tranexamic Acid — all drugs for Tranexamic Acid →

Sponsor

Izmir Ataturk Training and Research Hospital

Who can join

Adults 18 to 92, any sex, with Anterior Epistaxis or Tranexamic Acid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with epistaxis usually apply to the emergency department for initial treatment. According to recent research, tranexamic acid is effective in the treatment of epistaxis. The research compare the therapeutic superiority of saline with 500 and 1000 mg doses of topical tranexamic acid in the treatment of anterior epistaxis. The design of the phase 4 clinical trial was randomized controlled double-blind. A total of 152 cases in 3 groups were included in the study. Group 1 was treated with 1000 mg of tranexamic acid, group 2 with 500 mg of tranexamic acid, and group 3 with saline. The primary outcome of the study was bleeding control at the 5th and 10th minutes. Secondary outcomes were determined as the need for salvage therapy, recurrent bleeding within 24 hours, the presence of side effects, and the need for otorhinolaryngology consultation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial.
Arikan C, Akyol PY. · · 2024 · cited 1× · PMID 39351623 · DOI 10.1177/00368504241264993

Verify or expand the search:

Other trials of Tranexamic acid

Trials testing the same drug.

NCT07278037 — Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage · recruiting
NCT06599762 — Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia · Phase 2 · recruiting
NCT06657924 — Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery · Phase 2 · recruiting
NCT06806241 — Effects of Tranexamic Acid Irrigation on Impacted Third Molar Surgery · recruiting
NCT06419075 — Tranexamic Acid in Vaginal Reconstructive Surgery · Phase 4 · withdrawn

Other Izmir Ataturk Training and Research Hospital trials

Trials by the same sponsor.

NCT06990633 — Lynch Syndrome in Colorectal Cancer Surgery · not yet recruiting
NCT05902676 — The Effects Of Anticholinergic Burden On Daily Living Activities In Elderly Patients · unknown
NCT05776589 — The Effect of Intraoperative Ventilation Mode on Hemodynamics and Lung Dynamics · unknown
NCT05737459 — Sedation and Postoperative Cognitive Functions · completed
NCT04857216 — Comparison of the Block Characteristics of USG Guided Costoclavicular and Infraclavicular Block With the Perfusion Index · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06183918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Izmir Ataturk Training and Research Hospital
Last refreshed: 28 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06183918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing